LONA LeonaBio, Inc.

CIK 0001620463 49 ready 8-Ks latest August 26, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 49

Latest filing August 26, 2026, 4:05 PM ET

Top materiality 0.90

Event mix earnings ×21 · other_material ×17 · leadership ×5

Sentiment 6 pos · 15 neg · 28 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for LONA

Highest-materiality recent filing

Athira's Phase 2/3 LIFT-AD trial of fosgonimeton misses primary endpoint; biomarker data mixed

September 3, 2024, 7:59 PM ET other material materiality 0.90 negative item 8.01 item 7.01 item 9.01

Primary endpoint GST (p=0.70) and key secondary endpoints ADAS-Cog11 (p=0.35) and ADCS-ADL23 (p=0.61) not met; directionally favored fosgonimeton.
Prespecified subgroups (moderate AD, APOE4 carriers) showed numerically greater treatment effects; e.g., moderate AD ADAS-Cog11 delta -1.16 (p=0.39).

Read filing →

August 26, 2026, 4:05 PM ET other material materiality 0.70 positive item 8.01

LeonaBio enrolls 500th subject in Phase 3 ELAINE-3 trial; triggers warrant exercise

Enrolled 500th subject in Phase 3 ELAINE-3 trial (NCT05696626) for lasofoxifene + abemaciclib in ER+/HER2- ESR1-mutated metastatic breast cancer.
August 14, 2026, 4:07 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

LeonaBio Q2 2026 net loss $19.0M; cash $51.1M; ELAINE-3 enrollment on track

Net loss $19.0M ($0.80/sh) vs $7.0M ($1.78/sh) in Q2 2025; R&D spend up to $12.9M from $3.7M.
May 7, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

LeonaBio Q1 2026 net loss $32.9M ($1.73/share); cash burn $20.9M; ELAINE-3 enrollment target Q4 2026

Net loss of $32.9M ($1.73 per share) vs $9.1M ($2.34) in Q1 2025, driven by higher R&D spend.
March 31, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 9.01 item 2.01 item 1.01

LeonaBio files amended 8-K on Sermonix license, provides ELAINE-3 cost and timeline update

SEC granted waiver from providing Sermonix financial statements; license deal treated as business acquisition under Regulation S-X.
March 26, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

LeonaBio reports FY2025 net loss $105.6M; acquires Phase 3 lasofoxifene, raises $90M

Net loss of $105.6M ($24.70 per share) for FY2025 vs $96.9M loss in FY2024; R&D expenses rose to $85.6M on lasofoxifene license costs.
March 19, 2026, 7:59 PM ET other material materiality 0.75 neutral item 5.02 item 5.07 item 8.01 item 9.01

LeonaBio shareholders approve 2026 equity plan, 4x authorized share increase, and Sermonix warrant exercise

Authorized common shares increased from 90M to 400M; total capital stock from 190M to 500M.
December 18, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01 ◈ Equity Issuances ×2◈ Material Agreements

Athira Pharma licenses lasofoxifene rights, raises $90M in PIPE financing

Licensed exclusive rights to oral lasofoxifene from Sermonix and Ligand for $34.9M in equity, plus monthly payments and up to $100M milestones.
December 18, 2025, 6:59 PM ET M&A materiality 0.85 neutral item 1.01 item 3.02 item 7.01 item 8.01 item 9.01 ◈ Equity Issuances ×4

Athira Pharma raises ~$90M via PIPE and licenses lasofoxifene from Sermonix

PIPE gross proceeds ~$90M; investors include Commodore, TCGX, Perceptive; priced at $6.35/share with warrants.
November 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives

Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.
October 3, 2025, 7:59 PM ET regulatory materiality 0.60 positive

Athira Pharma regains Nasdaq minimum bid price compliance; delisting risk removed

Received Nasdaq notice on Oct 2, 2025 that closing bid price was $1.00+ for ten consecutive days.
September 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 9.01 ◈ Governance Changes

Athira Pharma to effect 10-for-1 reverse stock split on Sep 17 to meet Nasdaq minimum bid price

Effective Sept 17 at 5pm ET; shares start trading split-adjusted on Sep 18 under ticker ATHA.
August 7, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development

Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.
May 9, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track

Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.
April 16, 2025, 7:59 PM ET other material materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

Athira Pharma transfers to Nasdaq Capital Market; must regain $1 bid price by Oct 13, 2025

Approved transfer from Nasdaq Global Select Market to Capital Market effective April 17, 2025.
February 27, 2025, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Athira Pharma FY2024 net loss $96.9M; cash burn continues; ATH-1105 Phase 1 complete; fosgonimeton paused

Cash, cash equivalents and investments $51.3M as of Dec 31, 2024, down from $147.4M; net cash used in operations $97.2M.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Athira Pharma Q3 net loss $28.7M; LIFT-AD missed endpoints; exploring strategic alternatives

Net loss $28.7M ($0.75/sh) vs $33.0M ($0.87/sh) Q3 2023; cash $68.9M down from $147.4M at Dec 2023.
October 18, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 8.01

Athira Pharma receives Nasdaq bid price deficiency notice; stock below $1 for 30 days

Received Nasdaq notice on Oct 16, 2024 for non-compliance with minimum bid price of $1.00.
October 7, 2024, 7:59 PM ET leadership materiality 0.70 negative item 9.01

Athira Pharma terminates CFO/CBO and COO/CDO; grants retention equity to CEO and VP Finance

Andrew Gengos (CFO/CBO) and Rachel Lenington (COO/CDO) terminated Oct 1, 2024; severance payments of $363,750 and $375,000 respectively.
September 17, 2024, 7:59 PM ET other material materiality 0.85 negative item 2.05 item 9.01 ◈ Restructurings & Charges

Athira cuts 70% of workforce, pivots to ATH-1105 after LIFT-AD readout

Workforce reduction of ~70% (49 positions); one-time costs ~$2.8M third-quarter 2024.
September 3, 2024, 7:59 PM ET other material materiality 0.90 negative item 8.01 item 7.01 item 9.01

Athira's Phase 2/3 LIFT-AD trial of fosgonimeton misses primary endpoint; biomarker data mixed

Primary endpoint GST (p=0.70) and key secondary endpoints ADAS-Cog11 (p=0.35) and ADCS-ADL23 (p=0.61) not met; directionally favored fosgonimeton.
August 1, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Athira Pharma Q2 net loss $26.9M; LIFT-AD topline data expected Sept 2024

Cash, cash equivalents and investments were $91.8M as of June 30, 2024, down from $147.4M at Dec 31, 2023.
May 17, 2024, 7:59 PM ET litigation materiality 0.65 neutral item 8.01 item 9.01

Athira Pharma obtains preliminary approval for derivative lawsuit settlement with governance reforms

Court preliminary approval on May 3, 2024; final hearing set for July 18, 2024.
May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024

Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.
February 22, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 5.02 item 9.01 ◈ Earnings Releases

Athira Pharma FY2023 net loss $117.7M; LIFT-AD enrollment complete; data H2 2024

Net loss $117.7M ($3.09/sh) vs $95.6M ($2.53/sh) in FY2022; R&D spend rose to $93.8M.
January 8, 2024, 6:59 PM ET other material materiality 0.65 neutral item 2.02 item 5.02 item 9.01 ◈ executive_change

Athira reports $147.4M cash, completes LIFT-AD enrollment, CMO Moebius retiring

Preliminary cash, cash equivalents, and investments of ~$147.4M as of Dec 31, 2023.
November 9, 2023, 6:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases

Athira Pharma Q3 net loss widens to $32.7M, cash at $172.9M; LIFT-AD enrollment expected Q1 2024

Net loss of $32.7M ($0.87/share) vs $20.2M ($0.53/share) in Q3 2022; R&D expenses up $10.2M to $27.2M.
August 10, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Athira Pharma Q2 net loss $29.6M ($0.78/sh); cash $196.3M; LIFT-AD results H2 2024

Net loss $29.6M ($0.78/sh) vs $24.3M ($0.65/sh) in Q2 2022; R&D spend rose to $21.6M.
May 22, 2023, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 5.07 item 8.01 item 9.01 ◈ executive_change ×2◈ Shareholder Votes ×2

Athira Pharma appoints Andrew Gengos as CFO and CBO; Glenna Mileson retires

Andrew Gengos appointed CFO and CBO effective May 18, 2023, replacing Glenna Mileson who is retiring after eight years.
May 11, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Athira Pharma Q1 net loss $27.8M; focuses Alzheimer's trial on 40 mg dose

Net loss $27.8M ($0.73/share) vs $21.0M ($0.56) in Q1 2022; cash $219.9M.
March 23, 2023, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

Athira Pharma reports FY2022 net loss of $95.6M ($2.53/sh); cash $245.2M; $10M legal settlement

Net loss $95.6M ($2.53 EPS) vs $54.9M ($1.49 EPS) in 2021; R&D spend rose 44% to $61.5M.
November 10, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Athira Pharma reports Q3 net loss of $20.2M; LIFT-AD interim analysis supports continuation

Net loss of $20.2M ($0.53/shr) for Q3 2022 vs $15.7M ($0.42) in Q3 2021; cash $260.0M at Sep 30, 2022.
October 17, 2022, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 7.01 item 9.01

Athira gets positive interim analysis for Alzheimer's drug fosgonimeton, study continues

Independent data monitoring committee recommended continuation of LIFT-AD after unblinded interim analysis.
August 15, 2022, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Athira reports Q2 net loss $24.3M; ACT-AD Phase 2 Alzheimer's trial missed primary endpoint

Net loss $24.3M ($0.65/share) vs $14.0M ($0.38/share) in Q2 2021; cash $282.2M.
June 22, 2022, 7:59 PM ET other material materiality 0.80 negative item 8.01 item 7.01 item 9.01

Athira Phase 2 ACT-AD misses primary endpoint; monotherapy subgroup shows cognitive benefit

Primary endpoint ERP P300 latency not statistically significant in full mITT population (-6.02 ms vs placebo).
May 12, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Athira Pharma Q1 net loss $21.0M; topline ACT-AD Phase 2 data by end of 2Q22

Net loss $21.0M ($0.56/share) vs $8.9M ($0.25/share) in Q1 2021; R&D expense $14.5M, up from $7.4M.
March 24, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Athira reports FY2021 net loss $54.9M; ACT-AD Phase 2 data on track for Q2 2022

Net loss $54.9M ($1.49/share) vs $19.9M in 2020; R&D spend $42.8M, up from $13.3M.
October 21, 2021, 7:59 PM ET leadership materiality 0.85 negative item 5.02 item 8.01 item 9.01

CEO Leen Kawas resigns after special committee finds she altered images in doctoral research; Mark Litton appointed CEO.

Special committee concluded Dr. Kawas altered images in her 2011 dissertation and at least four research papers co-authored as a WSU graduate student.

Executive changes

Role change

Hans Moebius

Senior Scientific Advisor

LONA · LeonaBio, Inc.

Effective: 2024-01-05
Filed: January 8, 2024, 6:59 PM ET

Dr. Moebius voluntarily resigned his position as CMO effective January 5, 2024, and will continue employment on an at-will basis for a transition period ending March 31, 2024 (the “Transition Period”). During the Transition Period, Dr. Moebius will serve as a full-time employee in the role of Senior Scientific Advisor reporting to the Company’s Chief Executive Officer.

Departed

Glenna Mileson

Chief Financial Officer

LONA · LeonaBio, Inc.

Effective: 2023-05-18
Successor: Andrew Gengos
Filed: May 22, 2023, 7:59 PM ET

Glenna Mileson, the Company’s Chief Financial Officer, resigned from her position as Chief Financial Officer on May 18, 2023 effective immediately.

Appointed

Andrew Gengos

Chief Financial Officer and Chief Business Officer

LONA · LeonaBio, Inc.

Effective: 2023-05-18
Filed: May 22, 2023, 7:59 PM ET

the Company’s board of directors (the “Board”) appointed Andrew Gengos as the Company’s Chief Financial Officer and Chief Business Officer, effective May 18, 2023.

Appointed

Michael Panzara

director

LONA · LeonaBio, Inc.

Effective: 2022-03-18
Filed: March 21, 2022, 7:59 PM ET

appointed Dr. Michael Panzara as a director of the Company, effective immediately.

Appointed

Grant Pickering

Director

LONA · LeonaBio, Inc.

Effective: 2022-01-27
Filed: January 31, 2022, 6:59 PM ET

On January 27, 2022, the board of directors of Athira Pharma, Inc. (the “Company” or “Athira”), upon recommendation from the nominating and corporate governance committee of the Company’s board of directors (the “Board”), appointed Grant Pickering as a director of the Company, effective immediately.

Earnings & guidance

2026-Q1 EPS reported -$1.73 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

6 positive 15 negative 28 neutral

source · LONA on sec.gov